NASDAQ:SLN

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

Retrieved on: 
Thursday, May 30, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Conference, Therapy, Webcast

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will present at the Jefferies Global Healthcare Conference on Thursday, June 6th at 2:30 p.m.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will present at the Jefferies Global Healthcare Conference on Thursday, June 6th at 2:30 p.m.
  • ET.
  • The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com .
  • An archived replay of the webcast will be available following the conference.

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Retrieved on: 
Thursday, May 16, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Patient, JAMA, APOLLO, United States Treasury security, Therapy, American Medical Association, Journal, Research, G&A, Thalassemia, AstraZeneca, Polycythemia, Pharmaceutical industry

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
  • Collaboration Revenue: Collaboration revenue was £12.4 million, an increase of £1.0 million compared with the first quarter of 2023.
  • R&D Expenses: Research and development (R&D) expenses were £9.2 million, a decrease of £3.4 million compared to the first quarter of 2023.
  • G&A Expenses: General and administrative (G&A) expenses were £5.2 million, a decrease of £1.3 million compared to the first quarter of 2023.

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Retrieved on: 
Tuesday, April 30, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Webcast, Therapy, Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20th at 2:30 p.m.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20th at 2:30 p.m.
  • ET.
  • The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com .
  • An archived replay of the webcast will be available following the conference.

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Retrieved on: 
Monday, April 29, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Therapy, RNA, RNA interference, Management

Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.

Key Points: 
  • Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.
  • Iain Ross, Silence’s Chairman of the Board, commented, “Alistair has made significant contributions to the Board and the Company over the past nine years.
  • I want to recognise and thank Alistair for his input on behalf of the Board and management over almost a decade.
  • Mr. Gray stated, “Nearly 10 years after joining the Silence Board and at age 75, I feel the time is right to retire as a director.

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Retrieved on: 
Monday, April 8, 2024
Research, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, JAMA, American Medical Association, Cardiovascular disease, Serum, Patient, Journal, RNA, MD, Therapy, Moyamoya disease, Safety, Small RNA, APOLLO, ASCVD, Pharmaceutical industry

“Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.

Key Points: 
  • “Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.
  • Results from the single ascending dose portion of the trial in healthy participants were previously published in the April 2022 issue of JAMA, linked here .
  • Secondary outcomes included the serum levels of zerlasiran and effects on Lp(a) serum concentrations.
  • Zerlasiran is currently being evaluated in the ALPACAR-360 phase 2 study in subjects with baseline Lp(a) levels at or over 125 nmol/L at high risk of ASCVD events.

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, March 13, 2024
Health, Biotechnology, Research, AstraZeneca, Patient, EDT, Sale, G&A, Therapy, ATM, PV, Pharmaceutical industry

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights.
  • “2023 was a year of strong execution across Silence as we advanced our proprietary pipeline in the clinic,” said Craig Tooman, President and CEO of Silence.
  • In addition to zerlasiran, we’ve made excellent progress advancing divesiran in PV and remain on-track to report phase 1 data by June.
  • “We ended December 2023 with approximately $68.8 million and significantly increased our cash position in early 2024 to over $200 million,” said Rhonda Hellums, Chief Financial Officer of Silence.

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Retrieved on: 
Wednesday, March 13, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, MD, Patient, Cardiovascular disease, Small RNA, RNA, Moyamoya disease, ASCVD, Mole, Therapy, Tutoring

Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population.

Key Points: 
  • Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population.
  • These data demonstrated a highly significant reduction from baseline in Lp(a) compared to placebo to 36 weeks (primary endpoint).
  • Median percentage reduction in Lp(a) of 90% or greater were observed for both doses at week 36.
  • “We are excited about the emerging phase 2 data, which are very consistent with phase 1 results and support a competitive profile for treating patients with high Lp(a),” said Steven Romano, MD, Head of Research and Development at Silence.

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Pharmaceutical, Genetics, Health, EDT, Therapy, Webcast

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2023, on Wednesday, March 13, 2024.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2023, on Wednesday, March 13, 2024.
  • Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT that day to discuss the Company’s financial results and provide a general business update.
  • The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com .
  • The webcast will also be archived on the Company’s website.

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Retrieved on: 
Friday, February 23, 2024
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Therapy, AstraZeneca, Metabolism, SVP, Silence Therapeutics, Polycythemia, RNA, DSM-IV codes, Clinical trial, Small RNA, Biopharmaceutical, Pharmaceutical industry

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.
  • “This represents the first clinical milestone under our collaboration with AstraZeneca and the third program to enter the clinic from our mRNAi GOLD™ platform,” said Craig Tooman, President and CEO of Silence.
  • Silence and AstraZeneca initiated a multi-target collaboration in March 2020 focused on using Silence’s proprietary mRNAi GOLD™ platform to develop siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases.
  • Under the agreement, AstraZeneca will pay Silence an option fee of $10 million for each selected target at the point of candidate nomination.

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Retrieved on: 
Monday, February 5, 2024
Research, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Security (finance), ADS, Polycythemia, Therapy, Common stock, Morgan Stanley, PV, Sale, Private, Small RNA

Silence anticipates that the aggregate gross proceeds of the Private Placement will be approximately US $120.0 million (approximately £94.6 million2) before deducting placement agent fees and other offering expenses.

Key Points: 
  • Silence anticipates that the aggregate gross proceeds of the Private Placement will be approximately US $120.0 million (approximately £94.6 million2) before deducting placement agent fees and other offering expenses.
  • “Silence has long been a leader in the discovery and development of siRNA therapeutics but is beginning to be recognized on a global scale,” said Craig Tooman, President and CEO at Silence.
  • Morgan Stanley and William Blair are acting as lead placement agents and Chardan and H.C. Wainwright & Co. are acting as co-placement agents to the Company in connection with the Private Placement.
  • Silence has agreed to file a registration statement with the Securities and Exchange Commission (“SEC”) registering the resale of the ADSs sold in the Private Placement.